Skip to main content


The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

What's new


Steglatro (ertugliflozin) approved on its own and as part of two different combination therapies. Launch in early 2018. Continue Reading »


Novo Nordisk’s once-weekly injectable GLP-1 for type 2 diabetes recommended for approval, given strong A1c reduction and weight loss Continue Reading »

mom and baby

New CONCEPTT trial results show improved newborn health and more time-in-range in women with type 1 diabetes using CGM during pregnancy Continue Reading »


Results from the type 2 diabetes group in Dexcom’s DIaMonD trial show A1c and time-in-range benefits Continue Reading »


Trial results testing sotagliflozin and Farxiga in type 1 diabetes show greater A1c lowering and weight loss, plus continued conversation about small risk of DKA Continue Reading »


A recent trial comparing once-weekly GLP-1 agonists semaglutide and Trulicity found improved A1c and double the weight loss with semaglutide Continue Reading »

Victoza heart

FDA Approves New GLP-1 Label on Victoza to show that the medicine makes hearts healthier!  Continue Reading »

Research reveals improved A1c and weight loss benefits for people with type 1 diabetes on sotagliflozin, but a slightly increased risk of DKA Continue Reading »